Ultimi tweet

100 abstracts and 15 late-breaking abstracts include a Roche medicine. A broad oncology portfolio #ESMO19

Roche today announced that results from a number of studies across its comprehensive oncology portfolio, covering a broad range of cancers including bladder, lung and breast will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress, taking place from 27 September - 1 October in Barcelona, Spain.

A total of 100 abstracts and 15 late-breaking abstracts that include a Roche medicine will be presented at this year’s congress. "We are excited to present a number of key datasets across a broad range of diseases at ESMO this year, including results from our Tecentriq combination study in people with previously untreated advanced bladder cancer, the first positive Phase III cancer immunotherapy trial in this setting. In addition, we will present data from our Phase III Tecentriq monotherapy study in previously untreated advanced lung cancer,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development.

“We will also share data from a study using Foundation Medicine’s liquid (blood) biopsy, a more patient-friendly approach to diagnosing and treating cancer. The results of the first cohort of this study involving ALK+ non-small cell lung cancer patients who received Alecensa will be presented at the congress.” 

Commenta questo articolo:

Il tuo indirizzo email non sarà visibile agli altri utenti.
Il commento sarà pubblicato solo previa approvazione del webmaster.